Difference between revisions of "Copanlisib (Aliqopa)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "http://ascopubs.org/doi/abs/" to "http://ascopubs.org/doi/full/") |
m |
||
| Line 2: | Line 2: | ||
From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. | From [http://www.cancer.gov/drugdictionary?CdrID=653981 NCI Drug Dictionary]: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Follicular lymphoma]] | |
| − | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| Line 17: | Line 16: | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
| − | [[Category:PI3K inhibitors]] | + | [[Category:PI3K alpha inhibitors]] |
| + | [[Category:PI3K delta inhibitors]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
[[Category:Drugs FDA approved in 2017]] | [[Category:Drugs FDA approved in 2017]] | ||
Revision as of 02:41, 17 May 2018
Mechanism of action
From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.
Diseases for which it is used
History of changes in FDA indication
- 9/14/2017: Granted FDA accelerated approval "for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies."
Also known as
- Code name: BAY 80-6946
- Brand name: Aliqopa